Literature DB >> 17510856

Nosocomial fungal infections: epidemiology, diagnosis, and treatment.

Joshua Perlroth1, Bryan Choi, Brad Spellberg.   

Abstract

Invasive fungal infections are increasingly common in the nosocomial setting. Furthermore, because risk factors for these infections continue to increase in frequency, it is likely that nosocomial fungal infections will continue to increase in frequency in the coming decades. The predominant nosocomial fungal pathogens include Candida spp., Aspergillus spp., Mucorales, Fusarium spp., and other molds, including Scedosporium spp. These infections are difficult to diagnose and cause high morbidity and mortality despite antifungal therapy. Early initiation of effective antifungal therapy and reversal of underlying host defects remain the cornerstones of treatment for nosocomial fungal infections. In recent years, new antifungal agents have become available, resulting in a change in standard of care for many of these infections. Nevertheless, the mortality of nosocomial fungal infections remains high, and new therapeutic and preventative strategies are needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510856     DOI: 10.1080/13693780701218689

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  241 in total

Review 1.  Hospital-related outbreaks due to rare fungal pathogens: a review of the literature from 1990 to June 2011.

Authors:  E C Repetto; C G Giacomazzi; F Castelli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-03       Impact factor: 3.267

2.  Proteolytic cleavage of covalently linked cell wall proteins by Candida albicans Sap9 and Sap10.

Authors:  Lydia Schild; Antje Heyken; Piet W J de Groot; Ekkehard Hiller; Marlen Mock; Chris de Koster; Uwe Horn; Steffen Rupp; Bernhard Hube
Journal:  Eukaryot Cell       Date:  2010-11-19

Review 3.  Comparative genomics and the evolution of pathogenicity in human pathogenic fungi.

Authors:  Gary P Moran; David C Coleman; Derek J Sullivan
Journal:  Eukaryot Cell       Date:  2010-11-12

Review 4.  Candida albicans Biofilms and Human Disease.

Authors:  Clarissa J Nobile; Alexander D Johnson
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

Review 5.  Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework.

Authors:  Mary Ann Jabra-Rizk; Eric F Kong; Christina Tsui; M Hong Nguyen; Cornelius J Clancy; Paul L Fidel; Mairi Noverr
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

6.  Multicenter evaluation of Candida QuickFISH BC for identification of Candida species directly from blood culture bottles.

Authors:  Ayman M Abdelhamed; Sean X Zhang; Tonya Watkins; Margie A Morgan; Fann Wu; Rebecca J Buckner; DeAnna D Fuller; Thomas E Davis; Hossein Salimnia; Marilynn R Fairfax; Paul R Lephart; Melinda D Poulter; Sarah B Regi; Michael R Jacobs
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

Review 7.  Antibacterial and Antiviral Functional Materials: Chemistry and Biological Activity toward Tackling COVID-19-like Pandemics.

Authors:  Bhuvaneshwari Balasubramaniam; Sudhir Ranjan; Mohit Saraf; Prasenjit Kar; Surya Pratap Singh; Vijay Kumar Thakur; Anand Singh; Raju Kumar Gupta
Journal:  ACS Pharmacol Transl Sci       Date:  2020-12-29

8.  Candida glabrata persistence in mice does not depend on host immunosuppression and is unaffected by fungal amino acid auxotrophy.

Authors:  I D Jacobsen; S Brunke; K Seider; T Schwarzmüller; A Firon; C d'Enfért; K Kuchler; B Hube
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

9.  Molecular analysis of Candida albicans isolates from clinical specimens.

Authors:  Melahat Gurbuz; Ilknur Kaleli
Journal:  Mycopathologia       Date:  2009-12-10       Impact factor: 2.574

Review 10.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.